Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN programming

This article was originally published in The Tan Sheet

Executive Summary

FDA is requesting comments on development of CFSAN program priorities for FY 2006, according to a Federal Register notice published May 20. The plan will follow the five-section format of the FY 2005 plan, including: ensuring food defense and security; improving nutrition and dietary supplement safety; ensuring food/color additives and cosmetic safety; ensuring food safety "crosscutting" areas; and prioritizing ongoing activities. Comments are due July 19. CFSAN last released its list of goals in December (1"The Tan Sheet" Dec. 6, 2004, p. 7)...

You may also be interested in...



CFSAN 2005 Priorities: “Per Day” Labeling, NDI Revised Definitions

Publishing a final rule on "per day" labeling for dietary supplements is an "A" level priority for the Center for Food Safety & Applied Nutrition in the upcoming year

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel